[{"data":1,"prerenderedAt":168},["ShallowReactive",2],{"drug-atezolizumab":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":34,"contraindications":66,"warnings":67,"renal":75,"monitoring":76,"interactions":77,"review":78,"examples":81,"atc":87,"iran":89,"usApproval":101,"links":107,"populations":124},"atezolizumab",1,{"fa":7,"en":8},"آتزولیزوماب","Atezolizumab","antineoplastic-immunomodulating",{"fa":11,"en":12},"مهارکننده PD-L1","PD-L1 blocking antibody",[14],{"name":15,"market":16},"Tecentriq","US",[18,19,7],"tecentriq","تسنتریک",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":29,"refs":30},"inj-60","injection","iv","60 mg\u002FmL (840 mg\u002F14 mL, 1200 mg\u002F20 mL)",{"amount":27,"unit":28,"perVolumeMl":5},60,"mg",[16],[31],{"source":32,"section":33},"fda-tecentriq","3",[35],{"id":36,"disease":37,"label":38,"population":41,"type":45,"unit":28,"dose":46,"refs":48,"durationDays":51,"notes":52},"q3w","lung-cancer",{"fa":39,"en":40},"NSCLC، SCLC و سایر اندیکاسیون‌ها — ۱۲۰۰ mg وریدی هر ۳ هفته (یا ۸۴۰ mg هر ۲ هفته یا ۱۶۸۰ mg هر ۴ هفته)","NSCLC, SCLC and other indications — 1200 mg IV every 3 weeks (or 840 mg every 2 weeks or 1680 mg every 4 weeks)",{"minAge":42},{"value":43,"unit":44},18,"year","fixed",{"perDose":47,"dosesPerDay":5},1200,[49],{"source":32,"section":50},"2.2, Table 1",{"min":5,"max":5},[53,60],{"text":54,"refs":57},{"fa":55,"en":56},"فقط زیر نظر متخصص انکولوژی؛ ادامه تا پیشرفت بیماری یا سمیت غیرقابل‌قبول. تنظیم دوز برای عوارض و تداخل‌ها طبق برچسب.","Only under an oncologist; continue until progression or unacceptable toxicity. Dose adjustments for toxicity and interactions per label.",[58],{"source":32,"section":59},"2.2",{"text":61,"refs":64},{"fa":62,"en":63},"انفوزیون اول ۶۰ دقیقه، بعدی‌ها ۳۰ دقیقه اگر تحمل شد. کمکی NSCLC: حداکثر ۱ سال.","First infusion over 60 min, then 30 min if tolerated. Adjuvant NSCLC: up to 1 year.",[65],{"source":32,"section":59},[],[68],{"text":69,"refs":72},{"fa":70,"en":71},"واکنش‌های ایمنی شدید و کشنده (پنومونیت، کولیت، هپاتیت، اندوکرینوپاتی، نفریت، پوستی)؛ واکنش انفوزیون؛ عوارض پیوند آلوژن مغز استخوان؛ سمیت جنینی.","Severe and fatal immune-mediated reactions (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, skin); infusion reactions; complications of allogeneic HSCT; embryo-fetal toxicity.",[73],{"source":32,"section":74},"5",[],[],[],{"status":79,"reviewer":80,"date":80},"unverified",null,[82],{"regimen":36,"formulation":22,"input":83,"expect":85},{"ageYears":27,"weightKg":84},70,{"perDose":47,"mlPerDose":86},20,[88],"L01FF05",{"status":90,"forms":91,"refs":96},"registered",[92],{"code":93,"en":94,"fa":95},"52835","ATEZOLIZUMAB INJECTION, SOLUTION, CONCENTRATE INTRAVENOUS 60 mg\u002F1mL 20 mL","فرآورده تزریقی اتزولیزومب ۶۰ میلی‌گرم \u002F ۱ میلی‌لیتر ۲۰ میلی‌لیتر",[97],{"source":98,"section":99,"url":100},"darooyab-generic","G-4852\u002FAtezolizumab","https:\u002F\u002Fwww.darooyab.ir\u002FG-4852\u002FAtezolizumab",{"kind":102,"refs":103,"id":106},"BLA",[104],{"source":32,"section":105},"SPL approval \u002F marketing category","BLA761034",[108,111,115,119,122],{"kind":109,"url":110,"label":106},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=761034",{"kind":112,"url":113,"label":114},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=6fa682c9-a312-4932-9831-f286908660ee","FDA Tecentriq",{"kind":116,"url":117,"label":118},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa616035.html","Atezolizumab Injection",{"kind":120,"url":121,"label":88},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L01FF05",{"kind":123,"url":100,"label":8},"darooyab",{"pregnancy":125,"lactation":134,"pediatric":142,"geriatric":151,"reproductive":160},{"level":126,"text":127,"quote":130,"refs":131},"avoid",{"fa":128,"en":129},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Risk Summary Based on its mechanism of action [see Clinical Pharmacology (12.1) ] , TECENTRIQ can cause fetal harm when administered to a pregnant woman.",[132],{"source":32,"section":133},"8.1",{"level":126,"text":135,"quote":138,"refs":139},{"fa":136,"en":137},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for serious adverse reactions in breastfed infants from TECENTRIQ, advise women not to breastfeed during treatment and for at least 5 months after the last dose.",[140],{"source":32,"section":141},"8.2",{"level":143,"text":144,"quote":147,"refs":148},"caution",{"fa":145,"en":146},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Alveolar Soft Part Sarcoma The safety and effectiveness of TECENTRIQ for unresectable or metastatic ASPS have been established in pediatric patients aged 2 years and older.",[149],{"source":32,"section":150},"8.4",{"level":152,"text":153,"quote":156,"refs":157},"ok",{"fa":154,"en":155},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness were observed between patients aged 65 years or older and younger patients.",[158],{"source":32,"section":159},"8.5",{"level":143,"text":161,"quote":164,"refs":165},{"fa":162,"en":163},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Females Based on its mechanism of action, TECENTRIQ can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] .",[166],{"source":32,"section":167},"8.3",1792444707175]